The biopharmaceutical industry has made significant contributions toward providing better outcomes for numerous ailments but fixing the industry’s sagging image will require more than just developing drugs for dreaded diseases.
Deborah Waterhouse discusses her journey toward becoming CEO of ViiV Healthcare, an HIV joint venture between GSK, Pfizer and Shionogi, and her focus as a leader around innovation, building the “trust agenda” and company performance.
The Conference Forum’s invitation only R&D Leadership Summit sheds light on areas of focus and concern for top biopharmaceutical industry executives.
During my 17 years in pharmaceutical sales, I spent most of my time calling on GP/FPs and OB/Gyns, and for a time I was responsible for selling the antidepressant Remeron/Remeron Soltab.
The story of how John Leonard found his “next adventure” in pharma as president and CEO of Intellia Therapeutics — and what he’s doing to capitalize on it.
The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.
A few of our favorite Beyond The Printed Page articles from 2018.
How the interview with J&J’s Joaquin Duato originated over a year ago, and how the company is dealing with a recent negative article in the media.
Joaquin Duato, vice chairman of J&J’s executive committee, discusses how the company’s partnering and innovation-building model has evolved — and why.